BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:DDR inhibitor development is evolving rapidly\, marked by the 
 continuous emergence of new targets. AstraZeneca and Merck reaffirm their
  commitment to DDR inhibitors\, yet more pharmaceutical companies like Ro
 che and Gilead are diving into this therapeutic strategy\; biotech compan
 ies like Artios and IDEAYA remain dedicated to delivering safe and effect
 ive treatments to patients.\n\nThe unmet need for cancer therapies reinfo
 rces the critical importance for the community to unite at the 7th Annual
  DDR Inhibitors Summit in Boston\, January 2024\, to advance first-in-cla
 ss oncology treatments for patients.\n\nThis year's conference has underg
 one a renovation to maximize your experience\, featuring a new biomarkers
  pre-conference focus day with the goal of demystifying patient stratific
 ation and target ID. Two tracks for the main conference days follow\, cov
 ering early discovery of next-generation targets and clinical updates.\n\
 nJoin 150 peers in oncology innovation\, synthetic lethality\, medicinal 
 chemistry\, and clinical development\, at the exclusive DDR Inhibitors co
 nference - the sole industry-led event providing unmatched depth and insi
 ght into your challenges.\n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/199
 3688-2?pid=185Brochure:&nbsp\;https://go.evvnt.com/1993688-4?pid=185\n\nP
 rices:Conference + Focus Day - Solution Provider: USD 5097.00\,Conference
  Only - Solution Provider: USD 3699.00\,Conference + Focus Day - Academic
 : USD 3597.00\,Conference Only - Academic: USD 2599.00\,Conference + Focu
 s Day - Drug Developer: USD 4197.00\,Conference Only - Drug Developer: US
 D 2999.00\n\nSpeakers:&nbsp\;Alan D'Andrea\, Director - Center for DNA Da
 mage and Repair\, Dana-Farber Cancer Institute\, Alex gaither\, Vice Pres
 ident - Biology\, Ex Scientia\, Alison Karst\, Senior Research Scientist 
 - Oncology Biology\, Gilead Sciences\, Astrid Zimmermann\, Director - Onc
 ology Research Unit\, Merck KGaA\, Charles Sinclair\, Senior Director\, H
 ead of Translational Sciences\, Flagship Pioneering\, Daniel Speidel\, Ma
 naging Director and Co- Founder\, Breakpoint Therapeutics\, David Mankoff
 \, Associate Director of Education and Training and Scientific Advisory B
 oard Member and Co-founder\, University of Pennsylvania\, Duncan Hamish\,
  Wright Vice President - Translational Science\, Schrodinger Inc\, Eeson 
 Rajendra\, Director of DDR Biology\, Artios Pharma\, Hua Gong\, SVP - Tra
 nslational Medicine and Clinical Biomarker\, ZaiLaboratory\, Ioannis Goun
 aris\, Head of Clinical Development DDR\, Merck KGaA\, Isabel Jaco\, Seni
 or Principal Scientist\, Novartis Institutes for BioMedical Research\, Ja
 nn Sarkaria\, Radiation Oncology\, Mayo Clinic\, Jatinder Mukker\, Direct
 or - Clinical Pharmacology\, EMD Serono\, Julian Blagg\, Executive Vice P
 resident - Drug Discovery\, NeoPhore\, Katherine Pawelczak\, Chief Operat
 ing Officer and Vice President - Research\, Nerx BioSciences Inc.\, Kiera
 n Pinto\, Research Analyst\, Beacon Targeted Therapies\, Luke Piggott\, A
 ssociate Principal Scientist\, Debiopharm Research and Manufacturing SA\,
  Marco Maruggi\, Principal Scientist\, Pfizer\, Mark O'Connor\, Chief Sci
 entist - Early Oncology Discovery\, AstraZeneca\, Matthew Wongchenko\, Pr
 incipal Scientific Manager\, Genentech\, Michal Zimmermann\, Director of 
 Cancer Biology\, Repare Therapeutics\, Oren Gilad\, Chief Operating Offic
 er\, Aprea Theraputics\, Reeja Maskey\, Principal Research Scientist\, ID
 EAYA Biosciences\, Shailaja Kasibhatla\, Senior Vice President\, Boundles
 s Bio\, Sonia Iyer\, Director - Immuno-Oncology Strategy and Translationa
 l Medicine\, AstraZeneca\, Stephen Blakemore\, Vice President Translatina
 l Medicine\, Accent Therapeutics\, Timothy Yap\, Associate Professor - Me
 dical Institute for Applied Cancer Science\, MD Anderson Cancer Center\, 
 Ulrika Warpman Berglund\, CEO\, Oxcia\, Yong Cang\, Chief Scientific Offi
 cer and Co-founder\, Degron Therapeutics\n\nDate and Time:&nbsp\;30th Jan
 uary 2024 at 8:30 am to 1st February 2024 at 5:00 pm\n
DTEND:20240201T170000
DTSTAMP:20260512T223118Z
DTSTART:20240130T083000
LOCATION:The Colonnade Hotel\, 120\, Huntington Avenue\, Boston\, Massachu
 setts\, 02116\,
SEQUENCE:0
SUMMARY:DDR inhibitor development is evolving rapidly\, marked by the cont
 inuous emergence of new targets. AstraZeneca and Merck reaffirm their com
 mitment t...
UID:5fe5db89-a953-498f-bb6a-a5ee18270f68
END:VEVENT
END:VCALENDAR